FDA
-
-
-
-
-
-
-
CEL-SCI Multikine Phase 3 data accepted by Oral Oncology journal
-
-
-
-
-
-
-
CEL-SCI Announces Closing of Offering
-
-
-
-
-
-
-
CEL-SCI Reports Fiscal Second Quarter 2026 Results
-
-
-
-
-
-
-
CEL-SCI Reports Fiscal First Quarter 2026 Results
-
-
-
-
-
-
-
CEL-SCI Announces Proposed Public Offering
-
-
-
-
-
-
-
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
-
-
-
-
-
-
-
CEL-SCI Announces Pricing of Public Offering
-
335,387 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


